AMT MT STUDY GUIDE QUESTIONS WITH
CORRECT ANSWERS 2025
The three major phases of laboratory testing that a QA program should evaluate include
a. mean, standard deviation, and coefficient of variation.
b. pre-op, operative, and post-op.
c. pre-analytical, analytical, and post-analytical.
d. outpatient, inpatient, and non-patient. - CORRECT ANSWER -c. pre-
analytical, analytical, and post-analytical.
The process by which test results achieve the same high levels of accuracy and precision that ca
n be reproduced across measurement systems, laboratories and time is referred to as
a. laboratory process control.
b. laboratory calibration.
c. laboratory standardization.
d. laboratory verification. - CORRECT ANSWER -c. laboratory standardization.
What characteristics/functions do calibrators have?
a. They contain a known amount of analyte being tested.
b. They monitor the quality of reagents.
c. They monitor the quality of the sample.
d. They prevent equipment failure. - CORRECT ANSWER -
a. They contain a known amount of analyte being tested.
An abrupt demonstrated change in the mean is a
,a. shift.
b. trend.
c. variance.
d. deviation. - CORRECT ANSWER -a. shift.
Qualitative examinations are those that
a. qualify for waived testing.
b. produce non-numerical results.
c. do not require quality control.
d. do not require proficiency testing. - CORRECT ANSWER -b. produce non-numerical results.
A property of a test that is used to describe its quality (such as accuracy, precision, sensitivity, et
c.) is a
a. performance characteristic.
b. performance enhancement.
c. performance verification.
d. performance specification. - CORRECT ANSWER -a. performance characteristic
Under CLIA law, the process of testing and adjusting an instrument or test system to establish a
correlation between the measured response and the concentration or amount of the substance
that is being measuredby the test procedure is
a. calibration.
b. calibration verification.
,c. a lchallenge.
d. quality lcontrol. l- lCORRECT lANSWER l-a. lcalibration.
What lagency ldetermines lthe lcomplexity lof la llab ltest lsystem?
a. CMS
b. FDA
c. CDC
d. OSHA l- lCORRECT lANSWER l-b. lFDA
Certain lmoderate lcomplexity lmicroscopy ltests l(such las lurine lsediment levaluation land lskin lscra
lpings) lcommonly lperformed lby lhealthcare lproviders lin lthe loffice lsetting lare lclassified las
a. provider lmoderate lcomplexity ltests.
b. provider lexempt lstatus.
c. provider lpersonnel ltesting.
d. provider lperformed lmicroscopy. l- lCORRECT lANSWER l-d. lprovider lperformed lmicroscopy.
Policies land lprocedures lthat lare lintended lto lpromote lthe lquality land lvalidity lof ltest ldata land
le lnsure lthe lreliability land lintegrity lof ldata lgenerated lby lanalytical llaboratories lis lknown las
a. CLIA lLaw.
b. Quality lAssurance lPlan l(QAP).
c. Good lClinical lLaboratory lPractice l(GCLP).
d. Total lQuality lManagement l(TQM). l- lCORRECT lANSWER l-
c. lGood lClinical lLaboratory lPractice l(GCLP).
, Devices lbased lon lelectrophoretic lprinciples lare lused lin lthe lclinical llaboratory lto lperform lall lof
lt lhe lfollowing lexcept lto
a. measure lquantities lof lvarious lproteins lin lplasma, lurine, land lCSF.
b. separate lenzymes linto ltheir lcomponent lisoenzymes.
c. identify lantibodies.
d. measure lmolecules lin la lcharacteristic lspectrum lcalled lthe lemission lspectrum.
l- lCORRECT lANSWER l-
d. lmeasure lmolecules lin la lcharacteristic lspectrum lcalled lthe lemission lspectrum.
The lchemistry lmethodology lthat lis lbased lon lthe lfact lthat lsubstances lof lclinical linterest
lselectiv lely labsorb lor lemit lelectromagnetic lenergy lat ldifferent lwavelengths lis
a. flourometry.
b. atomicBabsorption.
c. spectrophotometry.
d. photometry. l- lCORRECT lANSWER l-c. lspectrophotometry.
Given l%T, lhow lis labsorbance lcalculated?
a. log l%T l- l2.
b. log l%T l+ l2.
c. 2 l+ llog l%T.
d. 2 l- llog l%T. l- lCORRECT lANSWER l-d. l2 l- llog l%T.
Prohibiting lrecapping lof lneedles lis lan lexample lof
CORRECT ANSWERS 2025
The three major phases of laboratory testing that a QA program should evaluate include
a. mean, standard deviation, and coefficient of variation.
b. pre-op, operative, and post-op.
c. pre-analytical, analytical, and post-analytical.
d. outpatient, inpatient, and non-patient. - CORRECT ANSWER -c. pre-
analytical, analytical, and post-analytical.
The process by which test results achieve the same high levels of accuracy and precision that ca
n be reproduced across measurement systems, laboratories and time is referred to as
a. laboratory process control.
b. laboratory calibration.
c. laboratory standardization.
d. laboratory verification. - CORRECT ANSWER -c. laboratory standardization.
What characteristics/functions do calibrators have?
a. They contain a known amount of analyte being tested.
b. They monitor the quality of reagents.
c. They monitor the quality of the sample.
d. They prevent equipment failure. - CORRECT ANSWER -
a. They contain a known amount of analyte being tested.
An abrupt demonstrated change in the mean is a
,a. shift.
b. trend.
c. variance.
d. deviation. - CORRECT ANSWER -a. shift.
Qualitative examinations are those that
a. qualify for waived testing.
b. produce non-numerical results.
c. do not require quality control.
d. do not require proficiency testing. - CORRECT ANSWER -b. produce non-numerical results.
A property of a test that is used to describe its quality (such as accuracy, precision, sensitivity, et
c.) is a
a. performance characteristic.
b. performance enhancement.
c. performance verification.
d. performance specification. - CORRECT ANSWER -a. performance characteristic
Under CLIA law, the process of testing and adjusting an instrument or test system to establish a
correlation between the measured response and the concentration or amount of the substance
that is being measuredby the test procedure is
a. calibration.
b. calibration verification.
,c. a lchallenge.
d. quality lcontrol. l- lCORRECT lANSWER l-a. lcalibration.
What lagency ldetermines lthe lcomplexity lof la llab ltest lsystem?
a. CMS
b. FDA
c. CDC
d. OSHA l- lCORRECT lANSWER l-b. lFDA
Certain lmoderate lcomplexity lmicroscopy ltests l(such las lurine lsediment levaluation land lskin lscra
lpings) lcommonly lperformed lby lhealthcare lproviders lin lthe loffice lsetting lare lclassified las
a. provider lmoderate lcomplexity ltests.
b. provider lexempt lstatus.
c. provider lpersonnel ltesting.
d. provider lperformed lmicroscopy. l- lCORRECT lANSWER l-d. lprovider lperformed lmicroscopy.
Policies land lprocedures lthat lare lintended lto lpromote lthe lquality land lvalidity lof ltest ldata land
le lnsure lthe lreliability land lintegrity lof ldata lgenerated lby lanalytical llaboratories lis lknown las
a. CLIA lLaw.
b. Quality lAssurance lPlan l(QAP).
c. Good lClinical lLaboratory lPractice l(GCLP).
d. Total lQuality lManagement l(TQM). l- lCORRECT lANSWER l-
c. lGood lClinical lLaboratory lPractice l(GCLP).
, Devices lbased lon lelectrophoretic lprinciples lare lused lin lthe lclinical llaboratory lto lperform lall lof
lt lhe lfollowing lexcept lto
a. measure lquantities lof lvarious lproteins lin lplasma, lurine, land lCSF.
b. separate lenzymes linto ltheir lcomponent lisoenzymes.
c. identify lantibodies.
d. measure lmolecules lin la lcharacteristic lspectrum lcalled lthe lemission lspectrum.
l- lCORRECT lANSWER l-
d. lmeasure lmolecules lin la lcharacteristic lspectrum lcalled lthe lemission lspectrum.
The lchemistry lmethodology lthat lis lbased lon lthe lfact lthat lsubstances lof lclinical linterest
lselectiv lely labsorb lor lemit lelectromagnetic lenergy lat ldifferent lwavelengths lis
a. flourometry.
b. atomicBabsorption.
c. spectrophotometry.
d. photometry. l- lCORRECT lANSWER l-c. lspectrophotometry.
Given l%T, lhow lis labsorbance lcalculated?
a. log l%T l- l2.
b. log l%T l+ l2.
c. 2 l+ llog l%T.
d. 2 l- llog l%T. l- lCORRECT lANSWER l-d. l2 l- llog l%T.
Prohibiting lrecapping lof lneedles lis lan lexample lof
